Pharmacogenetics of morphine: Potential implications in sickle cell disease

Deepika S. Darbari, Caterina P. Minniti, Sohail Rana, John Van Den Anker

Research output: Contribution to journalReview articlepeer-review

31 Scopus citations


Morphine is frequently used to treat painful episodes associated with sickle cell disease (SCD) but may fail to provide adequate analgesia in many patients. This concise review focuses on unique disease related changes in physiologic variables associated with SCD that impacts pharmacokinetics and pharmacodynamics of morphine and may contribute to the variability in analgesia. Emerging evidence suggests that the allelic variants in the genes involving the opioid (UGT2B7, OPRM1, and ABCB1 genes) and nonopioid system (COMT gene) can alter the efficacy of morphine.

Original languageEnglish (US)
Pages (from-to)233-236
Number of pages4
JournalAmerican Journal of Hematology
Issue number3
StatePublished - Mar 2008
Externally publishedYes

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Pharmacogenetics of morphine: Potential implications in sickle cell disease'. Together they form a unique fingerprint.

Cite this